Centbutindole vs trifluoperazine: a double-blind controlled clinical study in acute schizophrenia.
Twenty-nine acute schizophrenic patients were treated under double-blind conditions for six weeks with either centbutindole in a dose range of 3 mg/day to 4.5 mg/day or trifluoperazine in the dose range of 15 mg/day to 22.5 mg/day. Both drugs produced a significant improvement in initial psychopathology. No significant differences were demonstrated between the two treatment conditions.
Doongaji
D R
DR
Satoskar
R S
RS
Sheth
A S
AS
Apte
J S
JS
Desai
A B
AB
Shah
B R
BR
D000328:Adult; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D011719:Pyrazines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011897:Random Allocation; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D014268:Trifluoperazine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D011719:Pyrazines; D014268:Trifluoperazine; C039923:centbutindole